{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T18:17:29Z","timestamp":1778264249020,"version":"3.51.4"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thyroid Res"],"DOI":"10.1186\/s13044-024-00209-4","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:02:08Z","timestamp":1726444928000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Correlation between gene mutations and clinical characteristics in papillary thyroid cancer: a retrospective analysis of BRAF mutations and RET rearrangements"],"prefix":"10.1186","volume":"17","author":[{"given":"Daisuke","family":"Uno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhira","family":"Endo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomokazu","family":"Yoshizaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,16]]},"reference":[{"issue":"7","key":"209_CR1","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1158\/1055-9965.EPI-21-1440","volume":"31","author":"CM Kitahara","year":"2022","unstructured":"Kitahara CM, Schneider AB. Epidemiology of Thyroid Cancer. Cancer Epidemiol Biomarkers Prev. 2022;31(7):1284\u201397. https:\/\/doi.org\/10.1158\/1055-9965.EPI-21-1440.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"209_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"209_CR3","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1056\/NEJMra1501993","volume":"375","author":"JA Fagin","year":"2016","unstructured":"Fagin JA, Wells SAJ. Biologic and Clinical Perspectives on Thyroid Cancer. N Engl J Med. 2016;375(11):1054\u201367. https:\/\/doi.org\/10.1056\/NEJMra1501993.","journal-title":"N Engl J Med"},{"key":"209_CR4","doi-asserted-by":"publisher","first-page":"3551","DOI":"10.2147\/OTT.S160752","volume":"11","author":"J Tang","year":"2018","unstructured":"Tang J, et al. The role of radioactive iodine therapy in papillary thyroid cancer: an observational study based on SEER. Onco Targets Ther. 2018;11:3551\u201360. https:\/\/doi.org\/10.2147\/OTT.S160752.","journal-title":"Onco Targets Ther"},{"issue":"10","key":"209_CR5","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1089\/thy.2021.0091","volume":"31","author":"VF Koehler","year":"2021","unstructured":"Koehler VF, et al. Real-World Efficacy and Safety of Multi-Tyrosine Kinase Inhibitors in Radioiodine Refractory Thyroid Cancer. Thyroid. 2021;31(10):1531\u201341. https:\/\/doi.org\/10.1089\/thy.2021.0091.","journal-title":"Thyroid"},{"issue":"7","key":"209_CR6","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"Schlumberger M, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1406470.","journal-title":"N Engl J Med"},{"issue":"9940","key":"209_CR7","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","volume":"384","author":"MS Brose","year":"2014","unstructured":"Brose MS, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet (London, England). 2014;384(9940):319\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(14)60421-9.","journal-title":"Lancet (London, England)"},{"issue":"6","key":"209_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/jendso\/bvac048","volume":"6","author":"S Hamidi","year":"2022","unstructured":"Hamidi S, et al. Lenvatinib Therapy for Advanced Thyroid Cancer: Real-Life Data on Safety, Efficacy, and Some Rare Side Effects. J Endocr Soc. 2022;6(6):1\u20137. https:\/\/doi.org\/10.1210\/jendso\/bvac048.","journal-title":"J Endocr Soc"},{"issue":"1","key":"209_CR9","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1089\/thy.2022.0054","volume":"33","author":"M Kim","year":"2023","unstructured":"Kim M, et al. Lenvatinib Compared with Sorafenib as a First-Line Treatment for Radioactive Iodine-Refractory, Progressive, Differentiated Thyroid Carcinoma: Real-World Outcomes in a Multicenter Retrospective Cohort Study. Thyroid. 2023;33(1):91\u20139. https:\/\/doi.org\/10.1089\/thy.2022.0054.","journal-title":"Thyroid"},{"issue":"10","key":"209_CR10","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/nrendo.2011.142","volume":"7","author":"YE Nikiforov","year":"2011","unstructured":"Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011;7(10):569\u201380. https:\/\/doi.org\/10.1038\/nrendo.2011.142.","journal-title":"Nat Rev Endocrinol"},{"key":"209_CR11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/cancers13081932","volume":"13","author":"B Pekova","year":"2021","unstructured":"Pekova B, et al. NTRK Fusion Genes in Thyroid Carcinomas: Clinicopathological Characteristics and Their Impacts on Prognosis. Cancers (Basel). 2021;13:8. https:\/\/doi.org\/10.3390\/cancers13081932.","journal-title":"Cancers (Basel)."},{"key":"209_CR12","doi-asserted-by":"publisher","unstructured":"Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159(3):676\u2013690. https:\/\/doi.org\/10.1016\/j.cell.2014.09.050.","DOI":"10.1016\/j.cell.2014.09.050"},{"issue":"4","key":"209_CR13","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3803\/EnM.2023.1702","volume":"38","author":"J Lim","year":"2023","unstructured":"Lim J, et al. Different Molecular Phenotypes of Progression in BRAF- and RAS-Like Papillary Thyroid Carcinoma. Endocrinol Metab (Seoul, Korea). 2023;38(4):445\u201354. https:\/\/doi.org\/10.3803\/EnM.2023.1702.","journal-title":"Endocrinol Metab (Seoul, Korea)."},{"issue":"6","key":"209_CR14","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.ejso.2018.11.009","volume":"45","author":"TJ Musholt","year":"2019","unstructured":"Musholt TJ, et al. Detection of RET rearrangements in papillary thyroid carcinoma using RT-PCR and FISH techniques - A molecular and clinical analysis. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2019;45(6):1018\u201324. https:\/\/doi.org\/10.1016\/j.ejso.2018.11.009.","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"issue":"6","key":"209_CR15","doi-asserted-by":"publisher","first-page":"e22902","DOI":"10.1002\/jcla.22902","volume":"33","author":"Z Wang","year":"2019","unstructured":"Wang Z, Sun K, Jing C, Cao H, Ma R, Wu J. Comparison of droplet digital PCR and direct Sanger sequencing for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma. J Clin Lab Anal. 2019;33(6):e22902.","journal-title":"J Clin Lab Anal."},{"issue":"4","key":"209_CR16","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1210\/clinem\/dgaa913","volume":"106","author":"Y Liu","year":"2021","unstructured":"Liu Y, Wu S, Zhou L, Guo Y, Zeng X. Pitfalls in RET Fusion Detection Using Break-Apart FISH Probes in Papillary Thyroid Carcinoma. J Clin Endocrinol Metab. 2021;106(4):1129\u201338. https:\/\/doi.org\/10.1210\/clinem\/dgaa913.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"209_CR17","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1210\/er.2012-1038","volume":"34","author":"BR Haugen","year":"2013","unstructured":"Haugen BR, Sherman SI. Evolving approaches to patients with advanced differentiated thyroid cancer. Endocr Rev. 2013;34(3):439\u201355. https:\/\/doi.org\/10.1210\/er.2012-1038.","journal-title":"Endocr Rev"},{"issue":"3","key":"209_CR18","doi-asserted-by":"publisher","first-page":"112","DOI":"10.2183\/pjab.98.008","volume":"98","author":"M Takahashi","year":"2022","unstructured":"Takahashi M. RET receptor signaling: Function in development, metabolic disease, and cancer. Proc Japan Acad Ser B Phys Biol Sci. 2022;98(3):112\u201325. https:\/\/doi.org\/10.2183\/pjab.98.008.","journal-title":"Proc Japan Acad Ser B Phys Biol Sci."},{"issue":"March","key":"209_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fendo.2020.00102","volume":"11","author":"A Prete","year":"2020","unstructured":"Prete A, Borges de Souza P, Censi S, Muzza M, Nucci N, Sponziello M. Update on Fundamental Mechanisms of Thyroid Cancer. Front Endocrinol (Lausanne). 2020;11(March):1\u201310. https:\/\/doi.org\/10.3389\/fendo.2020.00102.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"209_CR20","doi-asserted-by":"publisher","first-page":"T79","DOI":"10.1530\/ERC-17-0354","volume":"25","author":"I Plaza-Menacho","year":"2018","unstructured":"Plaza-Menacho I. Structure and function of RET in multiple endocrine neoplasia type 2. Endocr Relat Cancer. 2018;25(2):T79\u201390. https:\/\/doi.org\/10.1530\/ERC-17-0354.","journal-title":"Endocr Relat Cancer"},{"issue":"8","key":"209_CR21","doi-asserted-by":"publisher","first-page":"T189","DOI":"10.1530\/ERC-18-0141","volume":"25","author":"LM Mulligan","year":"2018","unstructured":"Mulligan LM. 65 YEARS OF THE DOUBLE HELIX: Exploiting insights on the RET receptor for personalized cancer medicine. Endocr Relat Cancer. 2018;25(8):T189\u2013200. https:\/\/doi.org\/10.1530\/ERC-18-0141.","journal-title":"Endocr Relat Cancer"},{"issue":"9","key":"209_CR22","first-page":"1690","volume":"57","author":"YE Nikiforov","year":"1997","unstructured":"Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H, Fagin JA. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res. 1997;57(9):1690\u20134.","journal-title":"Cancer Res"},{"issue":"2","key":"209_CR23","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1054\/bjoc.1999.0921","volume":"82","author":"M Santoro","year":"2000","unstructured":"Santoro M, et al. Gene rearrangement and Chernobyl related thyroid cancers. Br J Cancer. 2000;82(2):315\u201322. https:\/\/doi.org\/10.1054\/bjoc.1999.0921.","journal-title":"Br J Cancer"},{"key":"209_CR24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.cancergen.2019.07.002","volume":"238","author":"JI Staubitz","year":"2019","unstructured":"Staubitz JI, et al. ANKRD26-RET - A novel gene fusion involving RET in papillary thyroid carcinoma. Cancer Genet. 2019;238:10\u20137. https:\/\/doi.org\/10.1016\/j.cancergen.2019.07.002.","journal-title":"Cancer Genet"},{"issue":"1","key":"209_CR25","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/1097-0142(19940101)73:1<176::aid-cncr2820730130>3.0.co;2-t","volume":"73","author":"M Zou","year":"1994","unstructured":"Zou M, Shi Y, Farid NR. Low rate of ret proto-oncogene activation (PTC\/retTPC) in papillary thyroid carcinomas from Saudi Arabia. Cancer. 1994;73(1):176\u201380. https:\/\/doi.org\/10.1002\/1097-0142(19940101)73:1<176::aid-cncr2820730130>3.0.co;2-t.","journal-title":"Cancer"},{"issue":"6","key":"209_CR26","doi-asserted-by":"publisher","first-page":"10637","DOI":"10.18632\/oncotarget.12885","volume":"8","author":"HG Vuong","year":"2017","unstructured":"Vuong HG, et al. The changing characteristics and molecular profiles of papillary thyroid carcinoma over time: A systematic review. Oncotarget. 2017;8(6):10637\u201349. https:\/\/doi.org\/10.18632\/oncotarget.12885.","journal-title":"Oncotarget"},{"key":"209_CR27","doi-asserted-by":"publisher","unstructured":"Santoro M, Moccia M, Federico G, Carlomagno F. \u201cRET Gene Fusions in Malignancies of the Thyroid and Other Tissues.,\u201d Genes (Basel). 2020;11(4). https:\/\/doi.org\/10.3390\/genes11040424.","DOI":"10.3390\/genes11040424"},{"key":"209_CR28","doi-asserted-by":"publisher","unstructured":"Paulson VA, Rudzinski ER, Hawkins DS. Thyroid cancer in the pediatric population. Genes (Basel). 2019;10(9).\u00a0https:\/\/doi.org\/10.3390\/genes10090723.","DOI":"10.3390\/genes10090723"},{"issue":"11","key":"209_CR29","doi-asserted-by":"publisher","first-page":"e0165596","DOI":"10.1371\/journal.pone.0165596","volume":"11","author":"Su","year":"2016","unstructured":"Su, et al. RET\/PTC Rearrangements Are Associated with Elevated Postoperative TSH Levels and Multifocal Lesions in Papillary Thyroid Cancer without Concomitant Thyroid Benign Disease. PLoS One. 2016;11(11):e0165596. https:\/\/doi.org\/10.1371\/journal.pone.0165596.","journal-title":"PLoS One."},{"key":"209_CR30","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/324686","volume":"2012","author":"G Treglia","year":"2012","unstructured":"Treglia G, Rufini V, Salvatori M, Giordano A, Giovanella L. PET Imaging in Recurrent Medullary Thyroid Carcinoma. Int J Mol Imaging. 2012;2012: 324686. https:\/\/doi.org\/10.1155\/2012\/324686.","journal-title":"Int J Mol Imaging"},{"issue":"4","key":"209_CR31","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1053\/j.semnuclmed.2023.01.003","volume":"53","author":"G Treglia","year":"2023","unstructured":"Treglia G, Rufini V, Piccardo A, Imperiale A. Update on Management of Medullary Thyroid Carcinoma: Focus on Nuclear Medicine. Semin Nucl Med. 2023;53(4):481\u20139. https:\/\/doi.org\/10.1053\/j.semnuclmed.2023.01.003.","journal-title":"Semin Nucl Med"},{"issue":"6892","key":"209_CR32","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949\u201354. https:\/\/doi.org\/10.1038\/nature00766.","journal-title":"Nature"},{"issue":"6","key":"209_CR33","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/s0092-8674(04)00215-6","volume":"116","author":"PTC Wan","year":"2004","unstructured":"Wan PTC, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116(6):855\u201367. https:\/\/doi.org\/10.1016\/s0092-8674(04)00215-6.","journal-title":"Cell"},{"issue":"5","key":"209_CR34","doi-asserted-by":"publisher","first-page":"818","DOI":"10.3349\/ymj.2004.45.5.818","volume":"45","author":"KH Kim","year":"2004","unstructured":"Kim KH, Kang DW, Kim SH, Seong IO, Kang DY. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J. 2004;45(5):818\u201321. https:\/\/doi.org\/10.3349\/ymj.2004.45.5.818.","journal-title":"Yonsei Med J"},{"issue":"2","key":"209_CR35","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/01.pas.0000176432.73455.1b","volume":"30","author":"AJ Adeniran","year":"2006","unstructured":"Adeniran AJ, et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol. 2006;30(2):216\u201322. https:\/\/doi.org\/10.1097\/01.pas.0000176432.73455.1b.","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"209_CR36","first-page":"1454","volume":"63","author":"ET Kimura","year":"2003","unstructured":"Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET\/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63(7):1454\u20137.","journal-title":"Cancer Res"},{"issue":"2","key":"209_CR37","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/path.1511","volume":"202","author":"V Trovisco","year":"2004","unstructured":"Trovisco V, et al. BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol. 2004;202(2):247\u201351. https:\/\/doi.org\/10.1002\/path.1511.","journal-title":"J Pathol"},{"issue":"8","key":"209_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12082056","volume":"12","author":"X Li","year":"2020","unstructured":"Li X, Kwon H. The impact of braf mutation on the recurrence of papillary thyroid carcinoma: A meta-analysis. Cancers (Basel). 2020;12(8):1\u201310. https:\/\/doi.org\/10.3390\/cancers12082056.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"209_CR39","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s12957-016-0979-1","volume":"14","author":"C Liu","year":"2016","unstructured":"Liu C, Chen T, Liu Z. Associations between BRAF(V600E) and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis. World J Surg Oncol. 2016;14(1):241. https:\/\/doi.org\/10.1186\/s12957-016-0979-1.","journal-title":"World J Surg Oncol."},{"issue":"2","key":"209_CR40","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1159\/000443032","volume":"38","author":"Q Zhang","year":"2016","unstructured":"Zhang Q, Liu SZ, Guan YX, Chen QJ, Zhu QY. Meta-analyses of association between BRAF V600E mutation and clinicopathological features of papillary thyroid carcinoma. Cell Physiol Biochem. 2016;38(2):763\u201376. https:\/\/doi.org\/10.1159\/000443032.","journal-title":"Cell Physiol Biochem"},{"issue":"8","key":"209_CR41","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1089\/thy.2011.0123","volume":"22","author":"C-K Jung","year":"2012","unstructured":"Jung C-K, et al. Mutational patterns and novel mutations of the BRAF gene in a large cohort of Korean patients with papillary thyroid carcinoma. Thyroid. 2012;22(8):791\u20137. https:\/\/doi.org\/10.1089\/thy.2011.0123.","journal-title":"Thyroid"},{"issue":"8","key":"209_CR42","first-page":"2726","volume":"10","author":"H Xie","year":"2018","unstructured":"Xie H, Wei B, Shen H, Gao Y, Wang L, Liu H. BRAF mutation in papillary thyroid carcinoma (PTC) and its association with clinicopathological features and systemic inflammation response index (SIRI). Am J Transl Res. 2018;10(8):2726\u201336.","journal-title":"Am J Transl Res"},{"issue":"25","key":"209_CR43","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1200\/JCO.2014.55.5094","volume":"32","author":"M Xing","year":"2014","unstructured":"Xing M, et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(25):2718\u201326. https:\/\/doi.org\/10.1200\/JCO.2014.55.5094.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"12","key":"209_CR44","doi-asserted-by":"publisher","first-page":"4390","DOI":"10.1210\/jc.2012-1775","volume":"97","author":"R Elisei","year":"2012","unstructured":"Elisei R, et al. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab. 2012;97(12):4390\u20138. https:\/\/doi.org\/10.1210\/jc.2012-1775.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"209_CR45","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s13139-015-0367-8","volume":"50","author":"SH Lee","year":"2016","unstructured":"Lee SH, et al. Association Between (18)F-FDG Avidity and the BRAF Mutation in Papillary Thyroid Carcinoma. Nucl Med Mol Imaging (2010). 2016;50(1):38\u201345. https:\/\/doi.org\/10.1007\/s13139-015-0367-8.","journal-title":"Nucl Med Mol Imaging (2010)."},{"issue":"5","key":"209_CR46","doi-asserted-by":"publisher","first-page":"662","DOI":"10.2967\/jnumed.114.150607","volume":"56","author":"J Nagarajah","year":"2015","unstructured":"Nagarajah J, Ho AL, Tuttle RM, Weber WA, Grewal RK. Correlation of BRAFV600E Mutation and Glucose Metabolism in Thyroid Cancer Patients: An 18F-FDG PET Study. J Nucl Med. 2015;56(5):662\u20137. https:\/\/doi.org\/10.2967\/jnumed.114.150607.","journal-title":"J Nucl Med"},{"issue":"44","key":"209_CR47","doi-asserted-by":"publisher","first-page":"41029","DOI":"10.1074\/jbc.M102824200","volume":"276","author":"X Xi","year":"2001","unstructured":"Xi X, Han J, Zhang JZ. Stimulation of glucose transport by AMP-activated protein kinase via activation of p38 mitogen-activated protein kinase. J Biol Chem. 2001;276(44):41029\u201334. https:\/\/doi.org\/10.1074\/jbc.M102824200.","journal-title":"J Biol Chem"},{"issue":"1","key":"209_CR48","doi-asserted-by":"publisher","first-page":"225","DOI":"10.7150\/ijbs.75459","volume":"19","author":"H Song","year":"2023","unstructured":"Song H, et al. HIF-1\u03b1\/YAP Signaling Rewrites Glucose\/Iodine Metabolism Program to Promote Papillary Thyroid Cancer Progression. Int J Biol Sci. 2023;19(1):225\u201341. https:\/\/doi.org\/10.7150\/ijbs.75459.","journal-title":"Int J Biol Sci"},{"issue":"4","key":"209_CR49","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.anl.2024.04.008","volume":"51","author":"T Yoshikawa","year":"2024","unstructured":"Yoshikawa T, et al. Association of (18)F- fluorodeoxyglucose uptake with the expression of metabolism-related molecules in papillary thyroid cancer. Auris Nasus Larynx. 2024;51(4):696\u2013702. https:\/\/doi.org\/10.1016\/j.anl.2024.04.008.","journal-title":"Auris Nasus Larynx"},{"issue":"1","key":"209_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"Haugen BR, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1\u2013133. https:\/\/doi.org\/10.1089\/thy.2015.0020.","journal-title":"Thyroid"},{"key":"209_CR51","unstructured":"National Comprehensive Cancer Network, NCCN Guidelines, version 4.2023 Thyroid Carcinoma. Available: \nhttps:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/thyroid.pdf. Accessed 29 Jan 2024."},{"issue":"9","key":"209_CR52","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1056\/NEJMoa2005651","volume":"383","author":"LJ Wirth","year":"2020","unstructured":"Wirth LJ, et al. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. N Engl J Med. 2020;383(9):825\u201335. https:\/\/doi.org\/10.1056\/NEJMoa2005651.","journal-title":"N Engl J Med"},{"issue":"10","key":"209_CR53","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1089\/thy.2022.0115","volume":"32","author":"NL Busaidy","year":"2022","unstructured":"Busaidy NL, et al. Dabrafenib Versus Dabrafenib + Trametinib in BRAF-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial. Thyroid. 2022;32(10):1184\u201392. https:\/\/doi.org\/10.1089\/thy.2022.0115.","journal-title":"Thyroid"}],"container-title":["Thyroid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13044-024-00209-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13044-024-00209-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13044-024-00209-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:03:19Z","timestamp":1726444999000},"score":1,"resource":{"primary":{"URL":"https:\/\/thyroidresearchjournal.biomedcentral.com\/articles\/10.1186\/s13044-024-00209-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,16]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["209"],"URL":"https:\/\/doi.org\/10.1186\/s13044-024-00209-4","relation":{},"ISSN":["1756-6614"],"issn-type":[{"value":"1756-6614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,16]]},"assertion":[{"value":"1 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Investigational Review Board of Kanazawa University (approval no. 202596). The consent to participate in the research was obtained through opt-out.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}